AbbVie Inc (ABBV)vsMerck & Company Inc (MRK)
ABBV
AbbVie Inc
$262.55
-0.20%
HEALTHCARE · Cap: $454.36B
MRK
Merck & Company Inc
$144.94
+0.78%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3% more annual revenue ($66.57B vs $64.39B). ABBV leads profitability with a 9.8% profit margin vs 4.8%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$262.55
$110.73 premium
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.94
$62.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 36/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?